LAWRENCEVILLE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it will ...

Genenta Science S.p.A. stock surged after ANEMOCYTE partnership. Discover temferon's cancer trial updates and what’s next.

Trials-in-progress poster of ongoing pivotal Phase 3 trial of DNA-mediated immunotherapy accepted at both IGCS and ESMO Congress 2025 ...

IMNN-001 program is currently advancing its OVATION 3 pivotal Phase 3 trial per planLAWRENCEVILLE, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- ...

Fourth-year biomedical engineering candidate Yining Zhu has been named a 2026 Siebel Scholar, an honor that recognizes students in bioengineering fields for exemplary achievement in academia, research ...

The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients ... to unforeseen ...

Despite the recent attention to the potential of developing and using gene therapy to treat several diseases, the therapy was ...

The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients ... to unforeseen ...

A study led by UCLA Health Jonsson Comprehensive Cancer Center investigators reveals how melanoma, the deadliest form of skin cancer, evolves to resist immunotherapy and identifies a potential ...

Dozens of new courses have entered our ranking of America’s 100 Greatest Public Courses since the last time we ranked the best golf resorts in the U.S. Just in the past two years, Black Desert Resort, ...